How has been the historical performance of Par Drugs & Che.?

Answer:The historical performance of Par Drugs & Che. shows a consistent growth in net sales and profitability over the years.

Breakdown:
Par Drugs & Che. has demonstrated a steady increase in net sales, rising from 55.85 Cr in Mar'20 to 100.97 Cr in Mar'25. The total operating income has followed a similar trend, reaching 100.97 Cr in Mar'25, compared to 46.32 Cr in Mar'19. The company's total expenditure, excluding depreciation, has also increased, amounting to 81.47 Cr in Mar'25. Operating profit (PBDIT) has fluctuated, peaking at 23.06 Cr in Mar'24 before dropping to 21.65 Cr in Mar'25. Profit before tax reached 17.92 Cr in Mar'25, while profit after tax was recorded at 13.36 Cr. The earnings per share (EPS) showed a slight decline from 11.79 in Mar'24 to 10.86 in Mar'25. The company's total assets increased significantly from 51.27 Cr in Mar'19 to 101.61 Cr in Mar'24, with total liabilities also rising but remaining manageable, as evidenced by the absence of long-term borrowings since Mar'22. Cash flow from operating activities improved to 20 Cr in Mar'24, contributing to a net cash inflow of 14 Cr for the same period. Overall, Par Drugs & Che. has shown a positive trajectory in its financial performance, marked by growth in sales, profits, and asset base.